At its Annual General Meeting on June 30, 2026, Akari Therapeutics, Plc shareholders failed to re-elect James Neal to the Board of Directors, ending his service as a director and his roles as Audit Committee member and Compensation Committee Chair. Consequently, the Board appointed Dr. Ray Prudo to the Audit Committee and Robert Bazemore as Chair of the Compensation Committee. Shareholders approved the issuance of ordinary shares under the ELOC Purchase Agreement, the issuance of Series H, I, and J Warrants for up to 4,411,764 ADSs, and a potential private placement resulting in a change of control. The company also authorized directors to allot shares up to a nominal amount of $20,000 through June 30, 2031. Akari Therapeutics is a biopharmaceutical company that develops therapies for inflammatory and immune-mediated diseases.

Akari Therapeutics, Plc amended its existing securities purchase agreement to consolidate the second and third tranches of a private placement into a single closing. The original agreement involved the sale of 1,470,588 American Depository Shares (ADSs) or prefunded warrants, plus Series H, I, and J warrants. Following the first closing on May 27, 2026, the amendment rescheduled the remaining two tranches to a combined closing on June 26, 2026, where the company issued the remaining 980,395 ADSs or prefunded warrants. Issuance of the Series Warrants remains contingent upon shareholder approval at the June 30, 2026, annual general meeting. Akari Therapeutics is a biopharmaceutical company.